We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





New Methodology to Detect SARS-CoV-2 That Produces Reliable Results More Quickly Could Be a Game-Changer

By LabMedica International staff writers
Posted on 21 Dec 2021
Print article
Illustration
Illustration

A new methodology to detect SARS-CoV-2 that can produce reliable results more quickly than other methods could be a game-changer in COVI-19 testing.

Researchers at the Binghamton University (Binghamton, NY, USA) have developed a nucleic acid sensor that has the potential to speed sample turn-around time while maintaining the sensitivity and specificity parameters that make molecular testing powerful.

Methods to detect SARS-CoV-2, the virus that causes COVID-19, come in two types. The first detects the virus protein or “antigen,” the basis of the rapid tests found at local stores, with results typically coming back in around 15 minutes. The second type are molecular tests designed to detect virus nucleic acid, which can take anywhere from one to three days to return results. In the very specific and sensitive molecular tests, specimens must be shipped to testing labs, where the samples are then processed and analyzed by technicians with specialized training. As a result, they’re considered by scientists as the gold standard for testing due to their reliability, although their long wait time makes them cumbersome for patients.

The nucleic acid sensor developed by the researchers is called an E-beacon and may lead to faster, more accurate test for coronavirus. Enzymatic beacons are engineered “bioconjugates” with two key components: a light-generating enzyme and a DNA probe. The components are stitched together via a recently-patented method. In the E-beacons prepared for SARS-CoV-2, the DNA probe recognizes a specific sequence in the virus’ spike gene; that recognition event in turn causes the light output from the attached enzyme to increase. The more virus nucleic acid in a sample, the brighter the light signal from the enzyme component of the E-beacon.

E-beacons can provide positive or negative results more rapidly than molecular tests, and without the expensive instrumentation required by polymerase chain reaction (PCR) based testing. The E-beacon experiments haven’t yet been done outside the lab, which is the likely next step. However, its applications could be a game-changer. For instance, users can access a walk-up, automated testing device that somewhat resembles a vending machine to deposit a testing swab into a collection port. The molecular tests would then run autonomously within the machine, sending out the results via cell phone in about two hours. E-beacons represent an attractive alternative to the current testing methods, and not just for SARS-CoV-2. Because of their modular design, they can be reconfigured easily for detecting other viral or bacterial pathogens.

“We focused on cutting down the wait time for molecular testing. We developed a nucleic acid sensor - we call it an E-beacon - that has the potential to speed sample turn-around time while maintaining the sensitivity and specificity parameters that make molecular testing so powerful,” said Brian Callahan, Binghamton University Associate Professor of Chemistry. “As of now, our E-beacons appear to be just as specific and even more sensitive than detection methods used in current SARS-CoV-2 molecular tests.”

Related Links:
Binghamton University 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
SARS-CoV-2 Antigen Test
NG-Test SARS-NG-Test SARS-CoV-2 Ag Cassette
New
Gold Supplier
Human Chorionic Gonadotropin (hCG) Test
OSOM hCG Combo Test
New
Microbial Infections In-Vitro Diagnostic Solution
Weezion dx

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.